Nevertheless, because of the high cancer risk, we suggest that NTHL1 should be included in cancer gene panels in clinical diagnostics, at least for the most common tumour types reported in the patients with pathogenic biallelic NTHL1 variants. This evidence concerns the gene NTHL1 and neoplasm.